

Best of 2024
ESMO
CONRAD DUBAI UAE
JUNE 8TH
BREAST CANCER

AGENDA



UAE Time	
8:30 - 9:00	Registration
9:00 - 9:05	Welcome & Introduction Prof. Humaid Al Shamsi & Dr. Aydah al Awadhi
Moderators: 🇦🇪 Dr. Aydah Al Awadhi & 🇸🇪 Dr. Omalkhair Aboulkhair	
9:05 - 9:15	🇸🇪 Dr. Fathi Azribi 1790 - Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER-positive, HER2-negative breast cancer harboring homologous recombination repair (HRR) deficiency or microsatellite instability (MSI): results of the international phase II DOLAF trial.
9:15 - 9:25	🇸🇪 Dr. Khalid Al-Baimani 1800 - IMpassion132 double-blind randomised phase 3 trial of chemotherapy (CT) _ atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC)
9:25 - 9:35	🇸🇪 Dr. Nadia Abdelwahed 1810 - Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A Phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC)
9:35 - 9:50	Panel Discussion
9:50 - 10:05	Coffee Break
10:05 - 10:25	🇸🇪 Satellite Symposium: Dr. Muhammad Farooq Latif Improving Survival Outcomes in 1st line HR+HER2- Advanced Breast Cancer
Moderators: 🇸🇪 Dr. Meteb Al Foheidi & 🇦🇪 Dr. Dalia Elshorbagy	
10:25 - 10:35	🇸🇪 Dr. Abdul Rahman El Kinge 182MO - Trastuzumab deruxtecan (T-DXd) vs Treatment of Physician's Choice (TPC) in Patients (pts) With HER2+ Metastatic Breast Cancer (mBC) Previously Treated With Trastuzumab Emtansine (T-DM1): Updated Overall Survival (OS) Results of the Randomized, Phase 3 DESTINY-Breast (DB-)02 Study
10:35 - 10:45	🇸🇪 Prof. Tarkan Yetisyigit 267MO - Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) Retreatment (RTx) After Recovery From Grade (Gr) 1 Interstitial Lung Disease/Pneumonitis (ILD) metastatic triple-negative breast cancer (aTNBC)
10:45 - 10:55	Panel Discussion



UAE Time

Moderators: Dr. Saeed Rafii & Dr. Aydah Al Awadhi

10:55 - 11:05	Dr. Maha Al Sindi 183MO - Capivasertib and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): second progression-free survival (PFS2) and time to first subsequent chemotherapy (TFSC) in the CAPItello-291 trial
11:05 - 11:15	Prof. Pierfranco Conte 1MO - HER2DX assay and survival outcomes: an individual-patient level metaanalysis of 2,031 patients with HER2-positive breast cancer
11:15 - 11:25	Dr. Husam Marashi 2MO - Dynamics of ESR1 mutation (ESR1m) circulating tumour DNA (ctDNA) in patients (pts) with estrogen receptor (ER)+ HER2- metastatic breast cancer (mBC) receiving camizestrant or fulvestrant: Exploratory analyses from the SERENA-2 trial
11:25 - 11:35	Panel Discussion
11:35 - 11:55	Satellite Symposium Moderated By : Dr. Aydah Al Awadhi Prof. Pierfranco Conte CAPItello-291: Unlocking TRU potential for HR+ mBC patients

Moderators: Dr. Faisal Alterkait & Dr. Dina Hamza

11:55 - 12:05	Dr. Atlal Abusanad 110MO - Statin use and early breast cancer survival: A Danish population-based cohort study using an emulated target trial approach results of the international phase II DOLAF trial.
12:05 - 12:15	Dr. Anwar Al Nouri 111MO - Tailored dose-dense versus standard adjuvant chemotherapy for highrisk early breast cancer: Efficacy outcomes and key subgroups after 10 years of follow-up in the randomized phase 3 PANTHER trial
12:15 - 12:25	Panel Discussion
12:25 - 12:45	Satellite Symposium By : Dr. Aydah Al Awadhi Abemaciclib, the Hope for High Risk Breast Cancer Patients

Moderator: Dr. Aydah Al Awadhi

DEBATE	12:45 - 13:05	Prof. Humaid Al Shamsi v/s Dr. Hassan Ghazal Debate topic: Should we do systemic surveillance imaging for breast cancer survivors?
	13:05 - 13:45	Lunch Break



UAE Time	
Moderators: 🇪🇦 Dr. Francois Calaud	
13:45 - 13:55	🇪🇦 Dr. Emad Dawoud 268MO - Safety of vaginal estrogen therapy after early-stage breast cancer: a nationwide population-based target trial emulation.
13:55 - 14:05	Panel Discussion
Moderators: 🇪🇦 Dr. Muhammad Farooq Latif & 🇪🇦 Dr. Sonia Otsmane	
14:05 - 14:15	🇪🇦 Prof. Marwan Ghosn 112MO - Neoadjuvant study of 12 months of Abemaciclib plus Letrozole vs. Chemotherapy in HR+/HER2_ highly proliferative (Ki67_20%) breast cancer: CARABELA (GEICAM/2019-01) Trial
14:15 - 14:25	🇪🇦 Dr. Hassan Ghazal 184MO - First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 in combination with endocrine therapy (ET) in patients (pts) with HR+/HER2_ metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors (CDK4/6i): safety and efficacy update
14:25 - 14:35	🇪🇦 Dr. Mohamed Omara 113MO - NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2_ early breast cancer (EBC)
14:35 - 14:45	Panel Discussion
14:45 - 14:55	Coffee Break
Moderators: 🇪🇦 Dr. Syed Hammad Tirmazy & 🇪🇦 Dr. Falah Al-Khatib	
14:55 - 15:05	🇪🇦 Dr. Nouri Bennini 266O - Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: results from an international cohort study
15:05 - 15:15	🇪🇦 Dr. Diaeddine Trad 109O - Adjuvant Endocrine Therapy for Premenopausal Invasive Lobular Carcinoma (ILC): Results from SOFT and TEXT phase III studies
15:15 - 15:25	Panel Discussion
Moderator: 🇪🇦 Dr. Aydah Al Awadhi	
DEBATE	🇪🇦 Dr. Dina Hamza v/s 🇪🇦 Dr. Saeed Rafii Debate topic: How would you sequence ADCs for patients with pretreated HR+/HER2- metastatic breast cancer?
15:45 - 15:55	Closing Remarks
15:55 - 16:00	Appreciation Ceremony